Hercules Capital, Inc. (HTGC) - Q2 2022 Filing Summary
Business Context and Reporting Period
This summary covers the quarterly report (Form 10-Q) for Hercules Capital, Inc., a Business Development Company (BDC) and Regulated Investment Company (RIC), for the period ended June 30, 2022. The Company provides senior secured loans to high-growth, venture capital-backed companies in technology, life sciences, and sustainable/renewable technology sectors.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2022 | Six Months Ended June 30, 2021 |
|---|---|---|
| Total Investment Income | $137.3 million | $138.3 million |
| Net Investment Income | $75.9 million | $71.5 million |
| Net Realized Gain (Loss) | $(4.5) million | $(6.5) million |
| Net Unrealized Appreciation (Depreciation) | $(85.1) million | $81.9 million |
| Net Increase (Decrease) in Net Assets | $(13.7) million | $146.9 million |
| Net Asset Value (NAV) per Share | $10.43 | $11.71 |
| Total Debt Outstanding | $1.52 billion | $1.25 billion |
| Cash and Cash Equivalents | $115.3 million | $18.4 million |
| Portfolio Turnover Rate | 8.88% | 19.26% |
Material Changes vs. Prior Period
- Net Loss vs. Net Gain: The Company reported a net decrease in net assets of $13.7 million for the six months ended June 30, 2022, compared to a net increase of $146.9 million in the prior year period. This reversal was primarily driven by a significant shift in unrealized valuation changes.
- Unrealized Depreciation: The portfolio experienced a net unrealized depreciation of $85.1 million in the current period, contrasting with $81.9 million of unrealized appreciation in the prior year. This was largely due to market volatility affecting the valuation of private equity and warrant holdings.
- Debt Structure: Total debt increased by approximately $270 million year-over-year. The Company issued $350 million in January 2027 Notes, $150 million in 2031 Asset-Backed Notes, and $50 million in June 2025 3-Year Notes. These proceeds were used to retire the 2022 Convertible Notes ($230 million) and 2022 Notes ($150 million).
- Portfolio Composition: The investment portfolio grew to $2.72 billion (fair value) from $2.43 billion. The "Drug Discovery & Development" sector remains the largest allocation at 38.6% of the portfolio.
- Realized Losses: Net realized losses were $4.5 million, primarily due to write-offs of investments in Regent Education, Medrobotics Corporation, and Genocea Biosciences, partially offset by gains from the sale of Black Crow AI, Inc. A $3.7 million loss on debt extinguishment was also recognized in Q1 2022.
Guidance, Outlook, and Risks
- Market Environment: Management notes continued volatility in U.S. and global capital markets due to the ongoing pandemic, geopolitical events (specifically the war in Ukraine), supply chain disruptions, and inflation. These factors create uncertainty regarding the financial condition of portfolio companies.
- Liquidity: As of June 30, 2022, the Company had $779.7 million in available liquidity, including $115.3 million in cash and significant unused capacity under its MUFG Bank Facility ($463.0 million) and SMBC Facility ($201.4 million).
- Dividend Policy: The Board declared a cash distribution of $0.35 per share and a supplemental distribution of $0.15 per share for the quarter, payable in August 2022. The Company aims to distribute approximately 90-100% of its taxable income.
- Valuation Risks: Approximately 94.7% of total assets are investments valued using Level 3 inputs (unobservable). Management highlights that fair value determinations involve significant judgment and may differ materially from values in a liquid market.
- Concentration Risk: Nine portfolio companies represented 5% or more of net assets as of June 30, 2022. The top holding, Corium, Inc., represented 10.1% of net assets.
Key Facts for Investor Verification
- NAV Decline: Verify the impact of the $85.1 million unrealized depreciation on the Company's ability to maintain its distribution policy, as distributions are funded by taxable income which may differ from GAAP net income.
- Debt Maturity Wall: Review the maturity schedule of the $1.52 billion debt portfolio. While the Company refinanced significant short-term debt in Q2, verify the weighted average cost of debt (4.0% for the six months ended June 30, 2022) against rising interest rate environments.
- Non-Accrual Status: Confirm the status of the $20 million (0.7% of portfolio) in non-accrual investments, specifically Tectura Corporation, which has been on non-accrual status.
- Unfunded Commitments: Note the $488.9 million in unfunded commitments available at the request of portfolio companies, which represents a potential future cash outflow requirement.
- Equity Offerings: Verify the utilization of the At-The-Market (ATM) equity distribution agreement, under which the Company raised approximately $147.1 million in net proceeds during the six-month period.